Find out now if you qualify. Time is limited to file a claim. You may be entitled to compensation. Fill out the form below to see if you qualify.
Boston Scientific ENDOTAK RELIANCE Alert
Information submitted will be transmitted to a law firm. This communication is intended to be an attorney-client communication for purposes of evaluating your claim and will be kept confidential by the law firm. The communication does not create an attorney-client relationship and no relationship is formed until a fee agreement is signed by you and the law firm. I also have read and agree to your Privacy Policy
File Your Claim Now
April 2022: The MDL Paraquat class action judge will have a status conference on April 1st to review where the litigation is headed and how best to take the bellwether lawsuits forward for trial in November 2022. 44 new paraquat lawsuits have been added to the MDL in the last two weeks. At this pace, April 2022 will be the busiest month for new files yet. Last week, the parties filed their class-action bellwether picks with the Paraquat MDL judge. Those choices, however, have not been made public.
May 2022: In the last month, over 50 new cases have been added to the Paraquat Lawsuit Multidistrict Litigation (MDL). A group of six patients was recently selected by the Paraquat MDL court for the initial Paraquat Parkinson's disease bellwether trials. As a result, the first trial in November 2022 is approaching soon. The strategy is to select 16 paraquat claims from among the almost 1000 Parkinson's disease litigation claims filed. Following some limited fact discovery in these instances, paraquat attorneys on both sides submitted a preference list to the MDL court, ranking the 16 cases in order of priority. Attorneys for plaintiffs seek the finest facts for their clients, while defense attorneys want the worst. The judge whittled the list down to six Paraquat claims based on these rankings.
CLAIM UPDATES
We are here to listen and help answer all your questions. Contact us today for a Free Claim Review by filling out the form above.
How the Defect Happens
If you or a family member have received one of the devices listed above, you may qualify to file a claim. Our experienced legal team will handle every aspect of the process, including gathering medical records and expert evaluations. We work on a contingency basis, meaning you pay nothing unless we win your case. Contact us today to find out if you qualify. Significant compensation may be available.
Seek Justice Today
Maryland Juvenile Detention
Abuse Claim Help
Jeff Brandow
Sexual Abuse
Claim Help
File Your Claim Now
Boston Scientific’s ENDOTAK RELIANCE family of defibrillation leads — including ENDOTAK RELIANCE, RELIANCE 4-SITE, and RELIANCE 4-FRONT models — has been linked to dangerous defects that can cause the device to fail during life-threatening heart rhythm events.
These leads have been on the market since 2003 for DF-1 models and around 2009–2010 for DF-4 models. Due to their long service life, approximately 354,000 affected leads remain implanted worldwide today.
The problem has been linked to design and material choices, including an ePTFE coating that is prone to calcification over time. This defect can manifest 8+ years after implantation, so patients who have had their devices for years may still be at risk.
"Trust our experienced team to handle your claim with care and commitment. Contact us today for reliable legal support."
Our dedicated team will fight for your rights and compensation. Confidentiality, Safety, & Justice are our top priorities
How to Qualify for a Depo-Provera Claim:
Use of Depo-Provera
Diagnosis of Brain Tumor
Document Evidence
Submit The Form Above
Depo-Provera is an injectable birth control containing the synthetic hormone medroxyprogesterone acetate, is linked to an increased risk of meningioma, a rare brain tumor. This risk was not adequately disclosed to consumers or medical professionals. Studies, including those published in the Journal of the American Medical Association (JAMA), have shown that long-term use of Depo-Provera significantly raises the risk of developing meningiomas.
Claims against Pfizer, Inc., the drug’s manufacturer, alleges that the company knew or should have known about the increased risk of meningiomas—brain tumors that can cause severe neurological symptoms—especially with prolonged use. The claims state that Pfizer failed to adequately warn doctors and patients, rushed the drug to market without sufficient long-term studies, and prioritized profits over safety.
Due to the rising number of claims against Pfizer regarding Depo-Provera and brain tumors have been consolidated into multidistrict litigation (MDL) in federal court. Affected individuals may seek compensation for medical expenses, long-term care, and other damages, with the potential for federal court consolidation of cases.
ENDOTAK Injury Claims
Justice & Compensation - Start Here
Even if you have not yet experienced symptoms, you may still be eligible if your device is on the affected list.
Defects in these devices are associated with:
Failure to convert ventricular arrhythmia, which can be fatal without immediate medical intervention.
Elevated shock impedance leading to ineffective therapy.
Lead calcification, making removal riskier and more complicated.
Reported Cases to Date:
386 serious injuries
16 confirmed deaths
Failure rates may reach 3% over 8 years, meaning over 10,000 patients could be at risk worldwide.
What Boston Scientific Knew
Evidence suggests Boston Scientific was aware, or should have been aware, of higher calcification rates in these leads compared to other manufacturers. Despite this, warnings to patients and physicians were delayed, and no adequate redesign was implemented in time to prevent harm.
Injuries & Risks
Who May Qualify for a Claim
You may qualify if:
You were implanted with a Boston Scientific ENDOTAK RELIANCE, RELIANCE 4-SITE, or RELIANCE 4-FRONT defibrillator lead.
You suffered complications, device failure, or required revision/replacement surgery.
A loved one with the device experienced sudden cardiac arrest or death.
